GEN Exclusives

More »

GEN Webinars

More »

GEN Presents An Educational And Informative Webinar

A Highly Sensitive, Versatile, Non-Optical Assay Platform for Analyzing Low-Abundance Proteins

  • Broadcast Date: Thursday, March 6, 2014
  • Time: 11:30 am ET, 8:30 am PT, 4:30 pm GMT



Quantitative proteomic assays are challenging, in part due to interferences from nontarget constituents. Wash steps that remove interfering species also tend to reduce weaker interactions of interest. Homogeneous acoustic assays enable quantitative biomarker measurements while avoiding these issues. One example is the measurement of a protein heteromer of relevance to inflammatory conditions.

The ViBE® instrument platform from Bioscale employs AMMP® (Acoustic Membrane MicroParticle) technology for automated, rapid design and configuration of highly sensitive assays to detect and quantify proteins, to sub-pg/mL concentrations, in complex biological samples.

AMMP uniquely integrates acoustic sensors, biological capture strategies, and magnetic microparticles into a sensitive, nonoptical, easy to use, and highly robust protein detection method. AMMP determines protein concentration by measuring the amount of analyte amplified by the mass of bound magnetic microparticles. The microparticles capture the analyte, reduce sample matrix interference, and transport the captured analyte to the acoustic sensor surface.

Carolus Therapeutics has developed a microplate-based acoustic quantitation assay, on the Bioscale VIBE platform, for measuring chemokine heteromers in patient plasma and sputum samples. This represents the first heteromer assay in patient samples, and may provide a noninvasive measure of the lung’s inflammatory state in diseases such as chronic obstructive pulmonary disease and Alpha 1 anti-trypsin deficiency.

You Will Learn

  • How the nonoptical Acoustic Assay technique is enabling, and how it differs from optical detection
  • How Acoustic Assays are automated on the VIBE instrument to create a novel, nonoptical protein analytic platform
  • Classes of biological targets in biomarker, inflammation, and cancer research
  • How to construct easy to use Acoustic Assays, based on AMMP, for protein targets you are working on today, using antibodies with which you are already familiar
  • How to “explant” your ELISA, Western blot or IHC assays to the more highly sensitive, automated, and quantitative Acoustic Assay format
  • How a development-stage pharmaceutical company has successfully deployed the VIBE platform to create novel, medically relevant assays for serious lung disorders

Who Should Attend

  • Biomarker investigators focused on cancer, inflammation, CNS, and cardiovascular research
  • Researchers studying protein-protein, -peptide and –small molecule interactions and antibody-antigen interactions
  • Scientists conducting ELISA, pK, or other protein assays
  • Developers of therapeutic antibodies
  • Developers of small molecule and biological therapeutics that interact with protein targets
  • Researchers seeking methods that replace or complement conventional protein analysis
  • Researches in academia and industry interested in novel quantitation methods in complex matrices

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.



  • Elisabeth Gardiner, Ph.D.,
  • Carolus Therapeutics
  • Martin Latterich, Ph.D.,
  • Bioscale


  • Tamlyn Oliver
  • Managing Editor
  • Genetic Engineering & Biotechnology News

Produced with support from